Lidocaine transdermal patch - Scilex Pharmaceuticals

Drug Profile

Lidocaine transdermal patch - Scilex Pharmaceuticals

Alternative Names: Lidocaine 1.8% patch - Scilex Pharmaceuticals; ZTlido

Latest Information Update: 17 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Scilex Pharmaceuticals
  • Class Acetanilides; Class Ib antiarrhythmics; Local anaesthetics; Small molecules
  • Mechanism of Action Sodium channel antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preregistration Postherpetic neuralgia

Most Recent Events

  • 14 Nov 2017 Preregistration for Postherpetic neuralgia in Europe (Transdermal)
  • 16 Sep 2017 Planned Prescription Drug User Fee Act (PDUFA) date for Postherpetic neuralgia in USA (Transdermal) is 2018-02-28
  • 29 Aug 2017 Scilex Pharmaceuticals announces intention to submit MAA in Europe, in the fourth quarter of 2017
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top